Home » Topics » Endocrine/metabolic, BioWorld Science

Endocrine/metabolic, BioWorld Science
RSS

Highly potent GH secretatogues discovered by Merck & Co.

April 6, 1998

Agents for hyperlipidemia under investigation at HMR

April 6, 1998

FDA approves Actonel for Paget's disease

April 3, 1998

Redux adverse effects reviewed at ACC

April 3, 1998

Gliatech's H3 antagonists show potential for treating obesity

April 3, 1998

NTE-122: effects on lipid metabolism and secretion in vitro

April 2, 1998

Merck & Co. identifies orally active, short-acting GH secretatogue

April 2, 1998

TheraTech, Palatin collaborate on oral peptides; first product will be a new treatment for ED

April 2, 1998

BioTime files NDA for blood plasma volume expander

April 2, 1998

New compounds synthesized at HMR upregulate LDL receptors

April 2, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
New schizophrenia targets challenge trial design
BioWorld
The search for better schizophrenia therapies is moving beyond dopamine toward a growing number of experimental targets. According to researchers, the repeated...
News in brief
BioWorld Asia
BioWorld Asia briefs for July 28, 2026
AIDS 2026: New targets for metabolic dysfunction despite ART
BioWorld
Although antiretroviral therapy (ART) can suppress HIV to undetectable levels, a growing body of evidence suggests that the virus leaves a lasting biological...
Fauci’s silence may put him in contempt of Congress
BioWorld
After repeatedly invoking the Fifth Amendment to every question asked during the July 29 hearing of the U.S. Senate Homeland Security Committee, Anthony Fauci,...